Haidong M Dong, MD, PhD

  • 13730 Citations
  • 47 Scopus h-Index
1992 …2019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Haidong M Dong is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 15 Similar Profiles
T-Lymphocytes Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Renal Cell Carcinoma Medicine & Life Sciences
Immunotherapy Medicine & Life Sciences
Dendritic Cells Medicine & Life Sciences
Immunity Medicine & Life Sciences
B7 Antigens Medicine & Life Sciences
Ligands Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2008 2019

Castration
Prostatic Neoplasms
Radiotherapy
Choline
Immunity
Melanoma
T-Lymphocytes
Therapeutics
Neoplasms
Biomarkers
T-Lymphocytes
Antibodies
Immunotherapy
Neoplasms
Kidney Neoplasms
Renal Cell Carcinoma
Ligands
Neoplasms
Cellular Immunity
Patient Care

Research Output 1992 2019

1 Citation (Scopus)

Biomarkers of hyperprogression and pseudoprogression with immune checkpoint inhibitor therapy

Failing, J. J., Dudek, O. A., Marin Acevedo, J. A., Chirila, R. M., Dong, H. M., Markovic, S. N. & Dronca, R. S., Aug 1 2019, In : Future Oncology. 15, 22, p. 2645-2656 12 p.

Research output: Contribution to journalReview article

Biomarkers
Neoplasms
Sample Size
Immunotherapy
Therapeutics
1 Citation (Scopus)

BRAF V600E-induced, tumor intrinsic PD-L1 can regulate chemotherapy-induced apoptosis in human colon cancer cells and in tumor xenografts

Feng, D., Qin, B., Pal, K., Sun, L., Dutta, S., Dong, H., Liu, X., Mukhopadhyay, D., Huang, S. & Sinicrope, F. A., Jan 1 2019, (Accepted/In press) In : Oncogene.

Research output: Contribution to journalArticle

Heterografts
Colonic Neoplasms
Apoptosis
Ligands
Drug Therapy

Circulating levels of PD-L1 and Galectin-9 are associated with patient survival in surgically treated Hepatocellular Carcinoma independent of their intra-tumoral expression levels

Sideras, K., de Man, R. A., Harrington, S. M., Polak, W. G., Zhou, G., Schutz, H. M., Pedroza-Gonzalez, A., Biermann, K., Mancham, S., Hansen, B. E., Bart Takkenberg, R., van Vuuren, A. J., Pan, Q., Ijzermans, J. N. M., Sleijfer, S., Sprengers, D., Dong, H. M., Kwekkeboom, J. & Bruno, M. J., Dec 1 2019, In : Scientific reports. 9, 1, 10677.

Research output: Contribution to journalArticle

Open Access
Galectins
Hepatocellular Carcinoma
Survival
Liver Transplantation
Biomarkers

Concordance of PD-1 and PD-L1 (B7-H1) in paired primary and metastatic clear cell renal cell carcinoma

Eckel-Passow, J. E., Ho, T. H., Serie, D. J., Cheville, J. C., Houston Thompson, R., Costello, B. A., Dong, H., Kwon, E. D., Leibovich, B. C. & Parker, A. S., Jan 1 2019, (Accepted/In press) In : Cancer medicine.

Research output: Contribution to journalArticle

Open Access
Neoplasms
Renal Cell Carcinoma
Clear-cell metastatic renal cell carcinoma
Survival
Biomarkers

Corrigendum to “Targeting B7-H1 (PD-L1) sensitizes cancer cells to chemotherapy” [Heliyon 4 (12) (December 2018) e01039] (Heliyon (2018) 4(12), (S2405844018323442), (10.1016/j.heliyon.2018.e01039))

Wu, X., Li, Y., Liu, X., Chen, C., Harrington, S. M., Cao, S., Xie, T., Pham, T., Mansfield, A., Yan, Y., Kwon, E. D., Wang, L. M., Ling, K. & Dong, H. M., Mar 1 2019, In : Heliyon. 5, 3, e01309.

Research output: Contribution to journalComment/debate

Open Access
Drug Therapy
Neoplasms
corrigendum